28th May 2009 07:00
28 May 2009
PROVEXIS PLC
("Provexis" or the "Company")
European Health Claim Adoption for Fruitflow
Provexis plc, the life-science business that discovers, develops and licenses scientifically-proven functional food, medical food and dietary supplement technologies, is pleased to announce the adoption of scientific substantiation of a health claim for the Company's Fruitflow® anti-thrombotic technology by the European Food Safety Authority ("EFSA").
The European Commission has introduced regulation aimed at harmonizing and approving nutrition and health claims on foods. EFSA intends to establish an EU-wide list of permitted claims by 2010 and health claims which do not comply will be prohibited. Provexis submitted a health claim dossier in late 2008 under Article 13(5) which regulates newly developed science or claims with proprietary data.
Following a review by the EFSA panel, it was judged that a cause and effect relationship has been established between consumption of Fruitflow® and the reduction of platelet aggregation in humans. EFSA has now adopted the scientific opinion substantiating the health claim and this will go through the final authorization procedure in the coming weeks.
Stephen Moon, Chief Executive of Provexis plc said:
"We understand that Fruitflow® is the first technology to have a health claim adopted by EFSA under Article 13(5) of the new legislation. While the process has required intensive resource allocation over the last few months, we are supportive of the new framework, given it clears the way for scientifically-substantiated products to prevail in the market. This is a major milestone for Provexis and one which we believe will have a very positive effect on current and future commercial negotiations. It is also recognition of the quality of our business, its technologies and our scientific and regulatory capabilities."
ENQUIRIES
Provexis plc Tel.01753 752 290
Stephen Moon, CEO
Steven Morrison, COO
Arbuthnot Tel.020 7012 2000
Tom Griffiths
Alasdair Younie
END
Related Shares:
Provexis